To use nanotechnology to create new value and help people lead healthier, happier lives.
To be an innovative pharma company carving out the future of therapeutics
Platform Technology: Micellar Nanoparticles
NanoCarrier’s micellar nanoparticle technology is a technology that uses biocompatible materials (poly (ethylene glycol) – poly (amino acid)) to encapsulate various substances into nano-sized micelles. Research and development is progressing to create new value by applying this technology as a DDS (Drug Delivery System) to medical field.
NanoCarrier is focusing on activities aimed at utilizing and practically applying our core technology, but also seek to strengthen our operating base through the early approval and sale of in-licensed products. Because the development of anticancer drugs and others costs an enormous amount of money and takes a long time.
Core technology-based revenue model
We aim to achieve early practical application and next-generation value creation through the fusion of our core technology with cutting-edge technologies
We independently develop the product until it reaches the market. In this case, we can expect sales of the products, but there is no such product as of now.
2）Joint research and development
We expect revenue of R&D cooperation fee from the partner. There are a few product pipelines in this category.
We expect revenues of up-front payment at the time of licensing, R&D cooperation fee for study drug, milestones according to the development stage, and royalty when the product goes on the market. There are a few product pipelines in this category. By strategically develop our business, we can expect revenues of up-front payment, R&D cooperation fee, milestones, and royalties to cover R&D cost and reduce the financial risk.
In-licensed product-based revenue model
We aim to form business partnerships with partners with high levels of expertise to make advanced therapeutics available to patients in Japan
We develop the in-licensed candidate product by ourselves until it reaches the market. In this case, we can expect sales of the products.
We develop the in-licensed candidate product to increase the product value and license the development / sales rights to other company.
In this case, we can expect revenues of an up-front payment, R&D cooperation fee, milestone payments, and royalties (and also reduce the financial risk).